Article and Video CATEGORIES

Cancer Journey

Search By

Is Nintedanib a new agent worthy of becoming a new treatment for advanced NSCLC?
gracevideo
Author
GRACE Videos and Articles

Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nintedanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.

[powerpress]

Discuss this post in the GRACE Discussion Forums

Next Previous link

Previous PostNext Post

Related Content

Recent Comments

JOIN THE CONVERSATION
ROS 1
By JanineT GRACE … on
Hi siigs, I'm sorry you're…
By JanineT GRACE … on
Tomorrow Saturday, Oct. 25, 2025
By JanineT GRACE … on
Blood Cancers OncTalk-Live, Free, Learn Sat. Oct. 25
By JanineT GRACE … on